Biodiversity, species preservation, ecosystem protection...
All are hot topics to which GenoScreen's genotyping solutions provide answers.

Press release - Researchers from GenoScreen and the Cardio-Thoracic Research Centre of Bordeaux (Inserm U1045) have demonstrated relationships between microorganisms in indoor air and those in asthmatic patients’ lungs. This work, published in the Journal of Allergy and Clinical Immunology and highlighted by the American Academy of Allergy, Asthma and Immunology (AAAI), also shows a variation in these micro- and mycobiota according to the patients’ inflammatory reaction type (T2 endotype).

GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex® Myc-TB test in Malaysia, Myanmar and Brunei.

This is confirmed by preliminary results of the PEOPLE study. This study is an opportunity for GenoScreen to apply its "Deeplex® Myc-Lep" sequencing assay for the first time to an international study.

Tuberculosis has been a major scourge since antiquity. The fight against this disease requires ever more efficient technologies. GenoScreen, a French biotech company, has recently developed a new weapon for predicting antibiotic resistance in the germs responsible for this disease. This new test, which comes in the form of a kit, quickly and efficiently detects the genetic mutations in the DNA of pathogenic germs and guides doctors in their medical prescriptions. This test is already being implemented in some thirty countries.

Following the Government's announcements concerning the COVID-19 pandemic, we are pleased to inform you that we have taken the necessary measures to ensure that all of our activities are maintained while guaranteeing the safety for our employees.

The innovative Deeplex® Myc-TB test for antibiotic resistance prediction in tuberculosis, created by GenoScreen, has been evaluated by an Indian research team. By testing approximately 40 clinical samples, this study validates the use of Deeplex® Myc-TB, by demonstrating its usability in hospital environments. These results confirm the interest of its deployment in hospital routines for the benefit of patients' health.

Press release - The innovative Deeplex® Myc-TB antibiotic resistance prediction test has been evaluated by an international research team. By analyzing data from more than 5,600 strains and samples of various origins and types, this study measures for the first time the sensitivity, specificity and detection limit of this test.

By continuing your visit to this site, you accept the use of statistics cookies